PEX13 Is Mutated in Complementation Group 13 of the Peroxisome-Biogenesis Disorders  by Liu, Yifei et al.
Am. J. Hum. Genet. 65:621–634, 1999
621
PEX13 Is Mutated in Complementation Group 13 of the Peroxisome-
Biogenesis Disorders
Yifei Liu,1 Jonas Bjo¨rkman,2 Aaron Urquhart,2 Ronald J. A. Wanders,3 Denis I. Crane,2 and
Stephen J. Gould1
1Department of Biological Chemistry, The Johns Hopkins University School of Medicine, Baltimore; 2School of Biomolecular and Biomedical
Science, Griffith University, Nathan, Queensland, Australia; and 3Departments of Clinical Biochemistry and Pediatrics, Academic Medical
Centre, University of Amsterdam, Amsterdam
Summary
The peroxisome-biogenesis disorders (PBDs) are a ge-
netically and phenotypically diverse group of diseases
caused by defects in peroxisome assembly. One of the
milder clinical variants within the PBDs is neonatal ad-
renoleukodystrophy (NALD), a disease that is usually
associated with partial defects in the import of peroxi-
somal matrix proteins that carry the type 1 or type 2
peroxisomal targeting signals. Here, we characterize the
sole representative of complementation group 13 of the
PBDs, a patient with NALD (patient PBD222). Skin fi-
broblasts from patient PBD222 display defects in the
import of multiple peroxisomal matrix proteins. How-
ever, residual matrix-protein import can be detected in
cells from patient PBD222, consistent with the relatively
mild phenotypes of the patient. PEX13 encodes a per-
oxisomal membrane protein with a cytoplasmically ex-
posed SH3 domain, and we find that expression of hu-
man PEX13 restores peroxisomal matrix-protein import
in cells from patient PBD222. Furthermore, these cells
are homozygous for a missense mutation at a conserved
position in the PEX13 SH3 domain. This mutation at-
tenuated the activity of human PEX13, and an analogous
mutation in yeast PEX13 also reduced its activity. The
mutation was absent in 1100 control alleles, indicating
that it is not a common polymorphism. Previous studies
have demonstrated extragenic suppression in the PBDs,
but the phenotypes of patient PBD222 cells could not
be rescued by expression of any other human PEX genes.
Taken together, these results provide strong evidence
that mutations in PEX13 are responsible for disease in
patient PBD222 and, by extension, in complementation
group 13 of the PBDs.
Received December 1, 1998; accepted for publication June 24, 1999;
electronically published August 10, 1999.
Address for correspondence and reprints: Dr. Stephen J. Gould, De-
partment of Biological Chemistry, The Johns Hopkins University
School of Medicine, 725 North Wolfe Street, Baltimore, MD 21205.
E-mail: Stephen.Gould@qmail.bs.jhu.edu
 1999 by The American Society of Human Genetics. All rights reserved.
0002-9297/1999/6503-0007$02.00
Introduction
Zellweger syndrome (ZS; MIM 214100), neonatal ad-
renoleukodystrophy (NALD; MIM 202370), infantile
Refsum disease (IRD; MIM 266510), and rhizomelic
chondrodysplasia punctata (RCDP; MIM 215100) to-
gether comprise the peroxisome-biogenesis disorders
(PBDs; Lazarow andMoser 1995). These phenotypically
heterogeneous diseases can be subdivided into two
groups, the Zellweger spectrum and the RCDP spec-
trum. Within the Zellweger spectrum, patients with ZS
display the most severe phenotypes. These patients rarely
survive the first year, exhibit pronounced hepatic, renal,
and neurologic deficits, and display relatively severe de-
fects in the import of all classes of peroxisomal matrix
proteins. The phenotypes of patients with NALD are
similar but less pronounced, and these individuals usu-
ally survive beyond the first year. Patients with IRD are
the most mildly affected individuals in this group and
in some instances may survive into their third or fourth
decade. Zellweger spectrum diseases can be caused by
defects in any of 10 different genes, eight of which are
known (Shimozawa et al. 1992; Dodt et al. 1995; Yah-
raus et al. 1996; Chang et al. 1997; Portsteffen et al.
1997; Reuber et al. 1997; Honsho et al. 1998; Warren
et al. 1998; Matsuzono et al. 1999; South and Gould
1999). Phenotype-genotype studies suggest that the dif-
ferent clinical phenotypes in the Zellweger spectrum are
due to differences in allele severity rather than to the
gene that is defective (Reuber et al. 1997; Chang and
Gould 1998; Collins and Gould 1999). In contrast, all
patients in the RCDP spectrum fall within a single com-
plementation group, CG11 (Braverman et al. 1997;
Motley et al. 1997; Purdue et al. 1997). These patients,
like those in the Zellweger spectrum, display develop-
mental delay and multitissue dysfunction but are distin-
guished by numerous features, including the presence of
pronounced rhizomelia and widespread epiphyseal cal-
cifications. In addition, patients with RCDP display a
much more restricted set of peroxisomal metabolic
abnormalities.
The underlying cause of the PBDs is a defect in the
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import of one or more classes of peroxisomal matrix
proteins, a phenotype that can be caused either by de-
fects in the peroxisomal matrix–protein import machin-
ery or by factors that are required for synthesis of per-
oxisome membranes. Peroxisomal proteins are encoded
by nuclear genes, contain peroxisomal targeting signals,
and are imported posttranslationally (Lazarow and Fu-
jiki 1985). Two types of peroxisomal targeting signals
have been identified, PTS1 and PTS2 (Subramani 1993).
PTS1 (Gould et al. 1989) is a C-terminal tripeptide of
the sequence serine-lysine-leucine-COOH, or a conser-
vative variant, and is found on the vast majority of per-
oxisomal proteins. PTS2 (Swinkels et al. 1991) is com-
monly found near the N-terminus of proteins and
consists of the sequence RLX5HL, but it explains the
targeting of only a handful of peroxisomal proteins.
The receptors for PTS1 and PTS2 have been identified
as the products of the PEX5 and PEX7 genes, respec-
tively, and mutations in these genes are responsible for
disease in complementation groups 2 and 11 of the PBDs
(Dodt et al. 1995; Braverman et al. 1997; Motley et al.
1997; Purdue et al. 1997). In addition to the PTS re-
ceptors, other peroxisome-biogenesis factors have been
found to be defective in the PBDs. The interacting ATP-
ases PEX1 and PEX6 are defective in complementation
groups 1 and 4 of the PBDs, the two most abundant
groups within the Zellweger spectrum (Fukuda et al.
1996; Yahraus et al. 1996; Portsteffen et al. 1997; Reu-
ber et al. 1997). Also, a trio of zinc-binding integral
peroxisomal membrane proteins, PEX2, PEX10, and
PEX12, have been identified as the factors defective in
groups 10, 7, and 3, respectively (Shimozawa et al. 1992;
Chang et al. 1997; Okumoto et al. 1998a, 1998b; War-
ren et al. 1998). More recently, defects in peroxisome-
membrane synthesis have been identified as a cause of
the PBDs, most notably in PEX16-defective CG9 cells
(Honsho et al. 1998; South and Gould 1999) and
PEX19-deficient cells from a 14th complementation
group, CG-J (Matsuzono et al. 1999).
The PTS receptors appear to be predominantly cy-
toplasmic proteins and may shuttle between the cyto-
plasm and peroxisome as they mediate matrix-protein
import (Marzioch et al. 1994; Dodt and Gould 1996).
Thus, they must interact with the peroxisome at several
points in the import process, the first of which is docking.
PEX13, PEX14, and PEX17 have been implicated in
PTS-receptor docking (Elgersma et al. 1996; Erdmann
and Blobel 1996; Gould et al. 1996; Albertini et al. 1997;
Huhse et al. 1998; Girzalsky et al. 1999) and may com-
prise a receptor-docking complex. Although candidate
human PEX13 and PEX14 genes have been identified
previously (Gould et al. 1996; Bjorkman et al. 1998;
Fransen et al. 1998) there has yet to be a patient who
is defective in these components of the peroxisomal pro-
tein–import apparatus. Shimozawa et al. (1998) re-
ported the identification of a patient with NALD who
defined a novel complementation group of the PBDs,
CG13, the 11th independent complementation group
within the PBDs. In the present study, we demonstrate
that this patient is defective in the import of multiple
peroxisomal matrix proteins and that this phenotype is
caused by a missense mutation, I326T, in the human
PEX13 gene.
Material and Methods
Cell Lines and Antibodies
The cell line from patient PBD222 has been described
previously (Shimozawa et al. 1998), as has the control
human skin-fibroblast line 5756T (Chang et al. 1999).
Cells were cultured in Dulbecco’s modified Eagle’s me-
dium supplemented with penicillin, streptomycin, and
10% FCS (Life Sciences). Rabbit polyclonal antibodies
to PMP70 were raised against the C-terminal 18 amino
acids of the protein (Ga¨rtner et al. 1992), rabbit poly-
clonal antibodies to human PEX14 were generated
against a fusion between PEX14 and maltose-binding
protein, rabbit polyclonal anti-SKL antibodies have been
described elsewhere (Gould et al. 1990), mouse anti-myc
monoclonal antibodies were obtained from the tissue-
culture supernatant of the hybridoma cell line 1-9E10
(Evan et al. 1985), and sheep polyclonal anticatalase
antibodies were obtained from The Binding Site (San
Diego). Fluorescently labeled goat secondary antibodies
were obtained from commercial sources.
Plasmids
The plasmid designed to express full-length human
PEX13 (pcDNA3-PEX13) has been described elsewhere
by Bjorkman et al. (1998). The plasmid designed to ex-
press the mutant form of PEX13 detected in patient
PBD222 cells, pcDNA3-PEX13/I326T, was created by
excising the 953-bp Asp718-NheI fragment from
pcDNA3-PEX13, excising the 300-bpNheI-EcoRI frag-
ment from pCR2.1-PEX13/PBD222 (see Mutation De-
tection below), and inserting these two fragments
between the Asp718 and EcoRI sites of pcDNA3 (In-
vitrogen). Prior reports have described the PEX
gene–expression vectors pcDNA3-PEX1 (Reuber et al.
1997), pcDNA3-PEX5 (Dodt et al. 1995), pcDNA3-
PEX6 (Yahraus et al. 1996), pcDNA3-PEX7 (Braver-
man et al. 1997), pcDNA3-PEX10 (Warren et al. 1998),
pcDNA3-PEX11a and pcDNA3-PEX11b (Schrader et
al. 1998), pcDNA3-PEX12 (Chang et al. 1997), and
pcDNA3-PEX16 (South andGould 1999). The plasmids
pcDNA3-PEX2, pcDNA3-PEX3, pcDNA3-PEX14,
and pcDNA3-PEX19 were constructed by inserting a
full-length cDNA for these human cDNAs (Shimozawa
et al. 1992; Braun et al. 1994; Fransen et al. 1998; Kam-
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merer et al. 1998) downstream of the CMV promoter
in pcDNA3. Prior reports have also described the per-
oxisomal marker-protein–expression vectors pcDNA3-
PAHXmyc (Mihalik et al. 1997), pcDNA3-NmycPECI
(Geisbrecht et al. 1999), pcDNA-NmycPTE1 (Jones et
al. 1999), and pcDNA3-NmycGOX (J. M. Jones and S.
J. Gould, unpublished data). The expression vector for
the N-terminal myc-tagged form of human catalase
(pcDNA3-NmycCatalase) was created by amplifying the
open reading frame of the human catalase cDNAby PCR
and cloning it downstream of the N-terminal myc-epi-
tope tag in pcDNA3-NmycPTE1 (Jones et al. 1999).
pDC120 is a HIS4-based replicating vector for the
yeast Pichia pastoris that contains the wild-type P.
pastoris PEX13 gene (Gould et al. 1996). An analo-
gous plasmid containing a mutant PEX13 gene that
lacks activity in vivo (pDC120/E291K) has also been
described (Gould et al. 1996). V334 of P. pastoris
Pex13p is analogous to I326 of human PEX13, and
pDC120 was modified to substitute a threonine for
valine 334, as follows: A 535-bp fragment containing
the PpPEX13 SH3 domain-coding sequence was am-
plified by PCR, with pDC120 as template and the
oligonucleotide primers 5′-GAAACGAATCATGGG-
CAAGTTGATGGG-3′ and 5′-AAACTGCAGCGGC-
AGGTTCTTCCTGAGCCTCAGGCACGGGTCGTT-
GATGTCGTTCAATGATTTCGACGTAATTGTAA-
GGTGTAAATCCAACCTTACCATC-3′, the latter in-
corporating the V334T coding-sequence change. The
EcoRI-PstI fragment from this PCR product was
cloned between the EcoRI and PstI sites of pDC120,
creating pDC120/V334T. The amplified portion of
this clone was sequenced to ensure the absence of any
unintended mutations.
Immunofluorescence
Human fibroblasts were grown on glass cover slips
until ready for analysis. The cells, still attached to cover
slips, were removed from the growth medium, washed
twice with Dulbecco’s modified phosphate-buffered sa-
line (DPBS; 0.2 mg/ml KCl, 0.2 mg/ml KH2PO4, 8 mg/
ml NaCl, 2.16 mg/ml Na2HPO47H2O, 0.11 mg/ml CaCl2,
and 0.95 mg/ml MgCl2 [pH 7.15]), and incubated in
3.7% formaldehyde in DPBS for 15–30 min. The cells
were then washed twice in DPBS and incubated in 1%
Triton X-100 in DPBS for 5 min to permeabilize the
cellular membranes. Next, the cells were washed twice
in DPBS and then incubated with primary antibodies for
15 min. Rabbit polyclonal anti-PMP70 antibodies were
used at a dilution of 1:300, rabbit polyclonal anti-
PEX14 antibodies were affinity purified and used at a
dilution of 1:100, rabbit polyclonal anti-SKL antibodies
were used at a dilution of 1:300, and sheep polyclonal
anticatalase antibodies were used at a dilution of 1:400;
and the tissue-culture supernatant from 1-9E10
cells—the source of mouse anti-myc monoclonal anti-
body—was undiluted. All antibodies were diluted in
DPBS with 0.1% BSA except for double-label experi-
ments with anti-myc antibodies, in which case they were
diluted into the 1-9E10 tissue-culture supernatant. After
10 washes with DPBS, the cells were incubated with
secondary antibodies for 15 min. At the end of this in-
cubation the cells were washed 10 times with DPBS and
mounted onto glass slides in a small volume (5–10 ml)
of 90% glycerol, 100mMTris-HCl (pH 8.5), and 0.01%
p-phenylenediamine.
Transfections and Calculation of Relative Rescue
Cells were transfected by electroporation, as described
by Chang et al. (1997), and were processed for immu-
nofluorescence two days after transfection. The numbers
of cells expressing each marker protein were counted,
and each expressing cell was placed into one of three
categories on the basis of the distribution of the marker
protein, as follows: (1) cytoplasmic only staining, in
which no peroxisomal staining could be detected; (2)
cytoplasmic plus peroxisomal staining, in which the cells
had significant cytoplasmic staining but also displayed
peroxisomal staining; and (3) peroxisomal only staining,
in which the protein appeared to be predominantly or
exclusively peroxisomal. The percentages of cells dis-
playing no import, partial import, and complete import
of the peroxisomal marker protein were calculated for
cells transfected with pcDNA3 (vector control), the
PEX13-expression vector (pcDNA3-PEX13), and the
PEX13/I326T–expression vector, pcDNA3-PEX13/
I326T. Corrected rescue values were calculated by sub-
tracting the percentage of import observed in cells trans-
fected with vector alone from the percentage of import
observed in cells transfected with the PEX13- and
PEX13/I326T–expression vectors. Relative rescue was
then obtained by dividing the corrected rescue values by
the corrected rescue value determined for the cells trans-
fected with the PEX13-expression vector. Relative com-
plete rescue was calculated in an analogous manner ex-
cept that only the cells demonstrating complete rescue
(i.e., import of the marker protein into peroxisomeswith
little or no cytoplasmic staining) were considered.
A minimum of 500 expressing cells were characterized
in each trial. All plasmids used in these experimentswere
of similar purity, as determined by UV-absorption spec-
trometry and agarose-gel electrophoresis. Furthermore,
two independent preparations of the pcDNA3-PEX13
and pcDNA3-PEX13/I326T plasmids were used in these
experiments (one set was used for assessing the import
of NmycCatalase (trial 1), NmycGOX (trials 1 and 2),
NmycPTE1, NmycPECI, PAHXmyc (trial 1), and en-
dogenous catalase; the second set of plasmids were used
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Table 1
Oligonucleotides Used in Amplifying PEX13 Exons and cDNA
Name Sequence (5′–3′)
HsPex13.1 GTCAGGGGTAGGAGCGGGAGCC
HsPex13.2 GTTCAACTGCAGGCAAACATGAAAG
HsPex13.3 CCAGGTCACCAGACCAACATACTAGTG
HsPex13.4 ACCGCCTCCTGCCAAGTCC
HsPex13.5 CAGTAGAATTTGTCATAGCACCAGG
HsPex13.6 TCCTCTGCCAGTTTTGAAGCTC
HsPex13.7 GCAAGCCATAGCCAGTGAAATATC
HsPex13.8 CTCTAAGTTAACTAACAATGAACAAGATCC
HsPex13.9 CCATTACTATTCTGTTGGACCTCC
HsPex13.12 TTCTGGCTAGCCTTGATGGCCAAACAACA
GGACGTA
HsPex13.13 AACAGATTCAAAGGCAGCTTCCTGTTCATCC
for assessing the import of NmycCatalase (trials 2 and
3), NmycGOX, (trial 3), and PAHXmyc (trial 2).
Mutation Detection
We isolated genomic DNA from control skin fibro-
blasts (5756T cells) and from patient PBD222 fibro-
blasts by using the PureGene kit as recommended by
the manufacturer (Gentra Systems). Genomic DNA
(100 ng) was then used as a template for the amplifi-
cation of the four PEX13 exons with use of the oli-
gonucleotides described (table 1), all of which are based
on the sequence of the PEX13 gene (Bjorkman et al.
1998). HsPEX13.1 and HsPEX13.4 were used for am-
plification of a 196-bp fragment containing exon 1,
HsPEX13.5 and HsPEX13.6 were used for amplifica-
tion of a 945-bp fragment containing exon 2,
HsPEX13.7 and HsPEX13.8 were used for amplifica-
tion of a 307-bp fragment containing exon 3, and
HsPEX13.9 and HsPEX13.2 were used for amplifica-
tion of a 393-bp fragment containing exon 4. Each PCR
product was purified and sequenced directly. We also
examined the structure of the PEX13 mRNA in patient
PBD222. Total RNA was isolated from control skin
fibroblasts (5756T cells) and from patient PBD222 fi-
broblasts with the PureScript kit as recommended by
the manufacturer (Gentra Systems). First-strand cDNA
was synthesized from patient PBD222 RNA with a
PEX13-specific oligonucleotide (HsPEX13.3) as a
primer. The cDNA product was then used as a template
for the amplification of the PEX13 open reading frame
with the PEX13-specific oligonucleotides HsPEX13.1
and HsPEX13.2. This PEX13 cDNA product was
cloned into the T/A vector pCR2.1 as recommended
by the manufacturer’s suggestions (Invitrogen). The
PEX13-derived fragment of the resulting plasmid,
pCR2.1-PEX13/PBD222, was sequenced in its entirety.
To determine the frequency of the PEX13/I326T mu-
tation, we amplified a 199-bp fragment of the PEX13
gene using two oligonucleotides (HsPex13.12 and
HsPex13.13) that flank the I326 codon. The fragment
amplified from the wild-type gene is cleaved into 164-
bp and 35-bp fragments by the restriction enzyme
BstZI7I, but the fragment amplified from the PEX13
gene with the I326T mutation is resistant to digestion
because the mutation eliminates the restriction-enzyme
site. This fragment of PEX13 was amplified from 51
control genomic DNA samples representing 102 PEX13
alleles. In each case, a single PCR product of the correct
size was obtained and no product was detected in control
samples that lacked genomic DNA (all amplifications
were carried out in sets of 16 samples, and positive
and negative control samples were included in each set
of reactions). The products of these reactions were then
digested with BstZ17I and separated by agarose-gel elec-
trophoresis, and the relative masses of the products were
determined by ethidium-bromide staining and interpo-
lation from standards of known size. We were unable
to detect undigested material from any of the 51 control
samples (data not shown), indicating that they lacked
the I326T mutation. This was in stark contrast to am-
plified material from patient PBD222 genomic DNA,
which was entirely resistant to digestion with BstZI7I,
as well as the amplification products from mixtures of
control and patient PBD222 genomic DNA, which were
only partially digested with BstZ17I (data not shown).
Yeast Studies
The P. pastoris PEX13-deletion mutant (arg4-1,
leu2D::ARG4, pex13D::LEU2, his4D::ARG4) has been
previously described by Gould et al. (1996), as have the
general procedures for the growth and manipulation of
P. pastoris strains (Crane and Gould 1994; Crane et al.
1994). The pex13D strain was transformed to histidine
prototrophy with the plasmids pDC120, pDC120/
E291K, and pDC120/V334T. Three independent trans-
formants for each were precultured in minimal glucose
medium lacking histidine (Crane and Gould 1994) and
then transferred to minimal methanol medium lacking
histidine, and the growth of each culture was monitored
by following the optical density at 600nm of the cultures.
Results
Phenotypes of Patient PBD222 Fibroblasts
The 11th independent complementation group of the
PBDs, CG13, is defined by a single patient with NALD
(Shimozawa et al. 1998), whom we designate patient
PBD222 in our patient-numbering system. Previous
studies have demonstrated that the PBDs can be caused
by defects in either peroxisomal matrix–protein import
or the synthesis of peroxisome membranes (Santos et al.
1988; Chang et al. 1999; Matsuzono et al. 1999; South
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Figure 1 Peroxisomal protein–import properties of patient PBD222 cells. The human skin–fibroblast cell line from patient PBD222 was
processed for single-label indirect immunofluorescence with rabbit antibodies specific for PMP70 (A), PEX14 (B), and fluorescein-labeled goat
antirabbit secondary antibodies. These cells were also processed for immunofluorescence with sheep antibodies specific for catalase (C) and
Texas red-labeled goat antisheep antibodies. Patient PBD222 cells were transfected with plasmids designed to express the peroxisomal marker
proteins NmycCatalase (D), Nmyc PTE1 (E), NmycPECI (F), NmycGOX (G), and PAHXmyc (H) and processed for immunofluorescence two
days later with mouse monoclonal anti-myc antibodies and Texas red-labeled goat antimouse secondary antibodies. These proteins are normally
imported into the peroxisome lumen (Mihalik et al. 1997; Geisbrecht et al. 1999; J. M. Jones and S. J. Gould, unpublished data; Jones et al.
1999). Patient PBD222 cells were also processed for single-label immunofluorescence with rabbit anti-SKL antibodies (I), which recognize
multiple PTS1-containing proteins (Gould et al. 1990), and fluorescein-labeled goat antirabbit secondary antibodies. Images were captured by
fluorescence microscopy on an Olympus BH2 fluorescence microscope and Kodak TMAX400 film. Bar = 15 mm.
and Gould 1999). To determine which process may be
defective in patient PBD222, we examined the ability of
patient PBD222 cells to import a variety of peroxisomal
membrane proteins and peroxisomal matrix proteins.
Patient PBD222 cells appeared to contain hundreds of
peroxisomes that could be labeled with antibodies to
either of two well-characterized peroxisomal membrane
proteins, PMP70 (Kamijo et al. 1990) and PEX14 (Fran-
sen et al. 1998) (fig. 1A and B). In contrast, the classic
peroxisomal matrix–protein marker, catalase, was dis-
tributed throughout the cytoplasm of patient PBD222
cells (fig. 1C). An Nmyc-tagged form of catalase con-
taining the 10 amino acid myc epitope at its N-terminus
was introduced into patient PBD222 cells and also was
found accumulated in the cells’ cytoplasm rather than
imported into their peroxisomes (fig. 1D). Catalase ter-
minates in an atypical form of the PTS1, KANL (Bell et
al. 1986; Purdue and Lazarow 1996), rather than in the
prototypical PTS1 of SKL (Gould et al. 1989), and is
the least efficiently imported peroxisomal matrix protein
known (Lazarow et al. 1982). To test whether patient
PBD222 cells were defective in import of other perox-
isomal matrix proteins, we examined the distribution of
two human proteins that terminate in the tripeptide
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Table 2
Ability of Different Human PEX Genes
to Restore Peroxisomal Protein Import
in Patient PBD222 Cells
Transfected Plasmid Catalase Import
pcDNA3 
pcDNA3-PEX1 
pcDNA3-PEX2 
pcDNA3-PEX3 
pcDNA3-PEX5 
pcDNA3-PEX6 
pcDNA3-PEX7 
pcDNA3-PEX10 
pcDNA3-PEX11a 
pcDNA3-PEX11b 
pcDNA3-PEX12 
pcDNA3-PEX13 
pcDNA3-PEX14 
pcDNA3-PEX16 
pcDNA3-PEX19 
SKLCOOH, the canonical type 1 peroxisomal targeting sig-
nal: peroxisomal thioesterase (PTE1; Jones et al. 1999)
and peroxisomal D3,D2 enoyl-CoA isomerase (PECI;
Geisbrecht et al. 1999). We also examined the distri-
bution of human peroxisomal glycolate peroxidase,
which terminates in the atypical PTS1, SKI (GOX; J. M.
Jones and S. J. Gould, unpublished data). Nmyc-tagged
forms of all three proteins (NmycPTE1, NmycPECI, and
NmycGOX) were predominantly cytoplasmic in patient
PBD222 cells (fig. 1E–G) although they are predomi-
nantly peroxisomal in normal human fibroblasts. Amyc-
tagged version of the PTS2-marker protein, phytanoyl-
CoA a-hydroxylase (PAHXmyc), which is efficiently tar-
geted to peroxisomes in normal human fibroblasts (Mih-
alik et al. 1997), was also predominantly cytoplasmic in
patient PBD222 cells (fig. 1H), demonstrating that the
protein-import defect of these cells also applies to PTS2-
targeted peroxisomal matrix proteins.
Given that patient PBD222 cells were derived from a
patient mildly affected with NALD, we would expect
that these cells would be able to import residual levels
of peroxisomal matrix proteins. Consistent with this pre-
diction, we did observe some peroxisomal import of the
peroxisomal marker proteins in ∼5%–15% of the pa-
tient PBD222 cells that were transfected with expression
vectors for NmycPTE1, NmycPECI, and PAHXmyc
(data not shown). Patient PBD222 cells showed no im-
port of NmycCatalase and imported detectable levels of
NmycGOX in !1% of expressing cells (data not shown).
The residual level of peroxisomal matrix–protein import
in patient PBD222 cells can also be visualized with an
anti-SKLCOOH antibody that recognizes multiple PTS1-
containing proteins. These antibodies detected the im-
port of at least some peroxisomal matrix proteins in
many patient PBD222 cells (fig. 1I).
PEX13 Is Defective in Patient PBD222
To identify the gene that is responsible for disease in
CG13 of the PBDs, we transfected patient PBD222 fi-
broblasts with pcDNA3-based plasmids that are de-
signed to express all known human PEX genes, includ-
ing PEX1 (Reuber et al. 1997), PEX2 (Shimozawa et
al. 1992), PEX3 (Kammerer et al. 1998), PEX5 (Dodt
et al. 1995), PEX6 (Yahraus et al. 1996), PEX7 (Brav-
erman et al. 1997), PEX10 (Warren et al. 1998),
PEX11a and PEX11b (Schrader et al. 1998), PEX12
(Chang et al. 1997), PEX13 (Bjorkman et al. 1998),
PEX14 (Fransen et al. 1998), PEX16 (South and Gould
1999), and PEX19 (Braun et al. 1994), as well as the
control vector, pcDNA3. Two days after transfection,
these cells were processed for indirect immunofluoresc-
ence with antibodies specific for human catalase, and
the subcellular distribution of catalase in each trans-
fected population was determined by visual inspection.
We observed that only expression of PEX13 rescued
catalase import in patient PBD222 cells (table 2 and fig.
2).
To determine whether the expression of PEX13 could
also restore the import of other peroxisomal matrix pro-
teins, we cotransfected patient PBD222 cells with
pcDNA3 or with pcDNA3-PEX13 together with plas-
mids designed to express PAHXmyc, NmycGOX,
NmycPTE1, NmycPECI, and NmycCatalase. Two days
after transfection, the cells were processed for indirect
immunofluorescence with antibodies specific for the myc
epitope tag and for PMP70, a marker of the peroxisome
membrane. In all instances, cotransfection with the
PEX13 expression vector resulted in significantly greater
import than occurred in cells transfected with vector
alone (table 3). The association of these proteins with
peroxisomes was demonstrated by their colocalization
with PMP70 (fig. 3). Differential permeabilization ex-
periments confirmed that the rescue observed in these
cells represented import into the peroxisome lumen (data
not shown).
These functional complementation studies provide
strong evidence that defects in PEX13were the probable
cause of disease in patient PBD222. To test this hy-
pothesis we sequenced the PEX13 gene from patient
PBD222. The organization of the PEX13 gene was re-
cently elucidated (Bjorkman et al. 1998), allowing us to
sequence all four coding exons of the PEX13 gene from
amplified fragments of genomic DNA. The sequence of
the PEX13 gene was determined both from patient
PBD222 and from an unaffected individual. As expected,
we detected a mutation in the PEX13 gene from patient
PBD222 (fig. 4). This mutation, a substitution of a thre-
onine codon for the isoleucine 326 codon, is referred to
as the I326T mutation. Patient PBD222 appears to be
homozygous for this mutation, because we were unable
to detect the wild-type sequence in this region of the
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Table 3
PEX13 Expression Rescues the Import of Multiple PTS1- and PTS2-
Containing Peroxisomal Marker Proteins in Patient PBD222 Cells
MARKER PROTEIN
PEROXISOMAL PROTEIN IMPORT (%)
pcDNA3 pcDNA3-PEX13
NmycCatalase 0/561 (0) 335/539 (62)
NmycGOX 4/1,081 (.4) 751/1,143 (66)
NmycPTE1 68/534 (13) 444/665 (67)
NmycPECI 77/565 (14) 373/505 (74)
PAHXmyc 11/659 (2) 444/626 (71)
Endogenous catalasea 17/543 (3) 130/587 (22)
a These numbers are not corrected for transfection efficiency.
Figure 2 Catalase is imported into peroxisomes of patient PBD222 after expression of PEX13. Patient PBD222 cells were transfected
with pcDNA3 (A and B) or pcDNA3-PEX13 (C and D). Two days after transfection, the cells were processed for indirect immunofluorescence
with sheep antibodies specific for human catalase (A and C) and rabbit antibodies specific for human PMP70 (B andD), followed by fluorescein-
labeled goat antisheep and Texas red-labeled goat antirabbit secondary antibodies. Images were captured by fluorescence microscopy on an
Olympus BH2 fluorescence microscope and Kodak TMAX400 film. Bar = 15 mm.
gene. Furthermore, our analysis of PEX13 cDNAs from
patient PBD222 revealed the presence of only one prod-
uct, that with the I326T mutation (data not shown).
Isoleucine 326 lies within the SH3 domain of PEX13, a
region of the protein that is required for function and
has been implicated in interactions with other peroxins
(Elgersma et al. 1996; Erdmann and Blobel 1996; Gould
et al. 1996; Girzalsky et al. 1999). Furthermore, this
residue is a conserved feature of PEX13 from a variety
of species, with either isoleucine or valine at this position
of the PEX13 protein from humans, nematodes (Cae-
norhabditis elegans), and the yeasts P. pastoris and Sac-
charomyces cerevisiae (Gould et al. 1996).
The I326T Mutation Attenuates PEX13 Activity
The hypothesis that the PEX13/I326T mutation is re-
sponsible for disease in patient PBD222, who is mildly
affected with NALD, makes two predictions. First, it
predicts that this mutation will reduce PEX13 activity
in vivo. Second, it predicts that this mutation will not
eliminate PEX13 activity in vivo, for if it did, patient
PBD222 should have displayed the more severe phe-
notypes of ZS rather than the milder phenotypes of
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Figure 3 PEX13 restores the import of multiple peroxisomal enzymes in patient PBD222 cells. Patient PBD222 cells were transfected
with pcDNA3-PEX13 and vectors designed to express myc-tagged versions of peroxisomal phytanoyl-CoA a-hydroxylase (A and B), glycolate
oxidase (C and D), and catalase (E and F) (pcDNA3-PAHXmyc, pcDNA3-NmycGOX, and pcDNA3-NmycCatalase, respectively). Two days
after transfection, the cells were processed for immunofluorescence with a mouse monoclonal antibody to the myc-epitope tag (A, C, and E)
and a rabbit antibody specific for PMP70 (B, D, and F), followed by fluorescein-labeled goat antimouse and Texas red-labeled goat antirabbit
secondary antibodies. Images were captured by fluorescence microscopy on an Olympus BH2 fluorescence microscope and Kodak TMAX400
film. Bar = 15 mm.
NALD. To test these predictions, we engineered the
I326T mutation into the PEX13 cDNA and assessed its
effects on PEX13 activity in vivo by using a functional
complementation assay.
Patient PBD222 cells were cotransfected with (1) the
plasmids pcDNA3, pcDNA3-PEX13, or pcDNA3-
PEX13/I326T, and (2) plasmids designed to express
myc-tagged versions of several human peroxisomal ma-
trix enzymes (PAHXmyc, NmycGOX, NmycPTE1,
NmycPECI, and NmycCatalase). Cells from each pop-
ulation were processed for immunofluorescence with an-
tibodies specific for the myc tag, and cells expressing the
marker proteins were scored on the basis of whether the
marker protein was cytoplasmic only (fig. 5A), cyto-
plasmic and peroxisomal (fig. 5B), or peroxisomal only
(fig. 5C). We also tested the ability of the wild-type and
mutant PEX13-expression vectors to rescue the import
of endogenously expressed catalase. The activity of the
PEX13/I326T cDNA displayed a relative rescue activity
with a range of 37%–85% of wild-type values, depend-
ing on the marker protein that was analyzed (table 4).
Data for all trials are presented. These results demon-
strate that the I326T mutation reduces but does not
eliminate PEX13 function, supporting the hypothesis
that the I326T mutation is responsible for disease in
patient PBD222.
An additional prediction from the mild phenotypes of
patient PBD222 is that its mutation may be particularly
poor at mediating complete import of peroxisomal pro-
teins. In our calculation of relative rescue, we included
cells that displayed either cytoplasmic and peroxisomal
staining or peroxisomal only staining. We recalculated
the rescue efficiencies for the PEX13- and PEX13/
I326T–expression vectors by using the more strict cri-
teria for import (peroxisomal only staining) to derive
relative complete rescue. A comparison between these
numbers and the relative rescue data suggest that the
I326T mutation had a particularly severe effect on the
ability of PEX13 to restore full peroxisomal protein im-
port in patient PBD222 cells, reducing its complete res-
cue to 2%–59%, relative to that of the wild-type PEX13
expression vector (table 4).
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Figure 4 The PEX13 mutation in patient PBD222. A genomic
DNA fragment spanning the length of exon 4 was amplified from
control and patient PBD222 genomic DNA and sequenced directly.
The sequencing chromatogram revealed the presence of a single mu-
tation in the fragment from patient PBD222 (B) that was not present
in the control sample (A). This mutation changes the T of the 326
codon (underlined in A) to a C, resulting in the substitution of thre-
onine for isoleucine at position 326 of the protein.
The Analogous Mutation in P. pastoris PEX13 also
Attenuates Activity
We have demonstrated previously the utility of using
yeast systems to study the effects of mutations in human
PEX genes (Dodt et al. 1995). Given that I326 of human
PEX13 is conserved as either an isoleucine or valine in
PEX13 from a variety of organisms, including P. pas-
toris, we decided to test the effect of an analogous mu-
tation in P. pastoris PEX13. The analogous residue in
this protein is valine 334, and we engineered a V334T
mutation into a P. pastoris PEX13-expression vector.
Previous studies have established that P. pastoris utilizes
peroxisomal enzymes for the metabolism of methanol
and requires functional peroxisomes as a sole carbon
source to grow on methanol (Gould et al. 1992). A P.
pastoris pex13D strain was transformed with plasmids
designed to express the wild-typePEX13 gene (pDC120)
and nonfunctional PEX13 gene (pDC120/E291K)
(Gould et al. 1996), as well as an analogous plasmid
(pDC120/V334T) designed to express the PEX13/
V334T gene. The growth, on methanol, of the resulting
strains was then monitored over a period of several days
(fig. 6). As previously demonstrated by Gould et al.
(1996), pDC120 can complement the peroxisomal pro-
tein–import defects and growth defect of the pex13D
strain, but the E291K mutation abrogates PEX13 func-
tion. Interestingly, we observed that the strain carrying
the PEX13/V334T–expression vector was able to grow
on methanol, although with a greatly extended lag phase
and reduced net growth. This intermediate phenotype
suggested that the V334T reduced but did not eliminate
PEX13 function as observed for the I326T mutation in
human PEX13.
The PEX13/I326T Mutation Is Not a Common
Polymorphism
Although the preceding data provide strong evidence
that the I326T mutation is responsible for disease in
patient PBD222, an alternative hypothesis is that (1) a
different gene is mutated in patient PBD222 cells, (2)
one or both of the mutations in this putative gene are
suppressed by transient overexpression of PEX13 in our
functional complementation assays, and (3) the PEX13/
I326T mutation is a silent polymorphism unrelated to
the disease. We have already noted that expression of
other human PEX genes failed to rescue the phenotypes
of patient PBD222 cells (table 2) and that the I326T
mutation has a significant effect on PEX13 activity. Nev-
ertheless, we tested whether the PEX13/I326T mutation
might be a polymorphism. We screened 102 PEX13
genes from 51 control individuals for the presence of
the I326T mutation. The PEX13/I326T mutation was
not detected in any of the control genomic DNA samples
(data not shown), suggesting that it is not a polymor-
phism.
Discussion
The initial report of patient PBD222 indicated that
this patient displayed the relatively mild phenotypes typ-
ical of patients with NALD (Shimozawa et al. 1998).
Here, we have examined the cellular phenotype of fi-
broblasts from this patient. On the basis of the import
of the peroxisomal membrane proteins PEX14 and
PMP70 we conclude that patient PBD222 cells do not
display a severe defect either in peroxisome synthesis or
in import of peroxisomal membrane proteins. However,
we found that patient PBD222 cells were defective in
import of all five peroxisomal matrix proteins that we
tested. These included catalase, the most inefficiently im-
ported peroxisomal matrix protein in mammalian cells
(Lazarow et al. 1982). It is notable that catalase contains
a variant form of PTS1, KANL (Purdue and Lazarow
1996), which may be responsible for its extremely in-
efficient import into peroxisomes. However, the perox-
isomal protein–import defects in patient PBD222 were
not restricted to catalase. We found that patient PBD222
cells also displayed defects in the import of peroxisomal
thioesterase, peroxisomal D3,D2 enoyl-CoA isomerase,
and peroxisomal glycolate oxidase (Geisbrecht et al.
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Table 4
The I326T Mutation Attenuates PEX13 Activity
MARKER PROTEIN
AND TRIAL
RELATIVE RESCUE
RELATIVE
COMPLETE RESCUE
WT I326T WT I326T
NmycCatalase:
Trial 1 100 37 100 8
Trial 2 100 38 100 2
Trial 3 100 62 100 18
NmycGOX:
Trial 1 100 65 100 39
Trial 2 100 58 100 37
Trial 3 100 71 100 59
NmycPTE1 100 77 100 45
NmycPECI 100 84 100 56
PAHXmyc:
Trial 1 100 85 ) )
Trial 2 100 61 100 16
Endogenous catalase 100 43 ) )
NOTE.—Values given are percents.
Figure 5 Different degrees of phenotypic rescue in functional complementation assays. Patient PBD222 cells were transfectedwithpcDNA3-
PEX13 and pcDNA3-NmycPECI. Two days later, these cells were processed for indirect immunofluorescence with a mouse monoclonal antibody
to the myc-epitope tag and fluorescein-labeled goat antimouse secondary antibodies. The transfected cells displayed three basic phenotype: no
import of NmycPECI (A), both cytoplasmic accumulation and peroxisomal import of NmycPECI (B), and predominantly peroxisomal staining
for NmycPECI (C). Images were captured by fluorescence microscopy on an Olympus BH2 fluorescence microscope and Kodak TMAX400
film. Bar = 15 mm.
1999; J. M. Jones and S. J. Gould, unpublished data;
Jones et al. 1999). We also found that patient PBD222
cells were defective in the import of a PTS2-protein
marker, phytanoyl-CoA a-hydroxylase (Mihalik et al.
1997). Thus, patient PBD222 cells displayed the typical
phenotypes of NALD: partial defects in the import of
PTS1- and PTS2-containing peroxisomal matrix pro-
teins, but no apparent defect in the import of peroxi-
somal membrane proteins or in the synthesis of
peroxisome membranes.
The phenotypes of patient PBD222 cells, like those of
all patients with NALD, predict that the mutations that
are responsible for disease will reduce but not eliminate
the activity of the affected gene. We found that expres-
sion of PEX13 restored peroxisomal protein import in
patient PBD222 cells and that patient PBD222 was ho-
mozygous for a missense mutation, I326T, in the PEX13
gene. This mutation attenuated but did not eliminate the
ability of PEX13 to rescue peroxisomal protein–import
defects in patient PBD222 cells, a result that is consistent
with the mild cellular and clinical phenotypes of patient
PBD222. In addition, we engineered the analogous mu-
tation (V334T) into the yeast P. pastoris PEX13 gene
and found that it caused a similar phenotype, reducing
but not eliminating PEX13 function.
These results strongly suggest that PEX13 is the gene
defective in patient PBD222 and complementation group
13 of the PBDs. However, it is necessary to consider the
possibility that the PEX13/I326T mutation might be a
silent polymorphism, and that the rescue of peroxisomal
protein import in patient PBD222 cells by PEX13might
represent an example of extragenic suppression, with the
causative mutation lying in a different human PEX gene.
However, several lines of evidence argue against this pos-
sibility. First, the I326T mutation was not detected in
1100 control alleles that were assayed, demonstrating
that it is not a common polymorphism. Second, we
found that none of the other known human PEX genes
(including PEX1, PEX2, PEX3, PEX5, PEX6, PEX7,
PEX10, PEX11a, PEX11b, PEX12, PEX14, PEX16,
and PEX19) were able to rescue peroxisomal protein
import in patient PBD222 cells. It is particularly notable
that none of the human homologues of yeast peroxins
that interact with yeast PEX13 (i.e., PEX5, PEX7, and
PEX14; see Elgersma et al. 1996; Erdmann and Blobel
1996; Gould et al. 1996; and Girzalsky et al. 1999) could
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Figure 6 The V334T mutation in P. pastoris PEX13 attenuates
its activity in vivo. Growth curves in minimal-methanol medium for
P. pastoris pex13D strains carrying the PEX13-expression plasmids
pDC120 (wild-type; denoted by blackened circles), pDC120/E291K
(inactive mutant; denoted by blackened triangles), and pDC120/
V334T (denoted by unblackened squares). Data represent the average
of three independent set of cultures, and the standard deviations are
presented as brackets above and below data point.
rescue the import defects in patient PBD222 cells. Third,
the I326T mutation significantly reduced PEX13 activ-
ity, and an analogous mutation in the P. pastoris PEX13
gene also reduced its activity. Finally, the efficiency with
which PEX13 rescued peroxisomal protein import in
patient PBD222 cells was roughly equivalent to the ef-
ficiency with which we could introduce the PEX13-ex-
pression vector into patient PBD222 cells. In our pre-
vious report of extragenic suppression in the PBDs
(between PEX1 and PEX6), we observed that extragenic
suppression was much less efficient (25%) than com-
plementation with the gene that was mutated in the cells
(Geisbrecht et al. 1998).
The high relative activity retained by the PEX13/
I326T cDNA (40%–80%, depending on themarker pro-
tein being assayed) is not without precedent for mild
alleles of human PEX genes. The common G843D mu-
tation in PEX1 retains ∼20% of the complementing ac-
tivity of wild-type PEX1 (Reuber et al. 1997), and the
H290Q mutation in PEX10 retains 50%–85% comple-
menting activity as compared with that of the wild-type
PEX10 gene (Warren et al. 1998). Furthermore, it
should be noted that the activities reported for the
PEX13/I326T cDNA were not determined in a PEX13-
null cell line but in a cell line—that of patient
PBD222—that retains some PEX13 activity. In contrast,
the high activities for the PEX1/G843D and PEX10/
H290Q mutations were determined against a null back-
ground in cell lines that lacked any residual PEX1 or
PEX10 activity, respectively. It should also be noted that
there is no heterozygote phenotype in the PBDs, indi-
cating that the amount of gene function required to gen-
erate full rescue may be significantly less than the full
activity of the wild-type PEX13 gene. As such, the rel-
ative rescue activities determined in our functional com-
plementation assay may be significantly higher than the
actual amount of gene function encoded by mutant
alleles.
PEX13 was initially ruled out as the gene that is de-
fective in patient PBD222 (Shimozawa et al. 1998). This
conclusion was made on the basis of the observation
that expression of a PEX13 cDNA failed to rescue ma-
trix-protein import in patient PBD222 cells. However,
the PEX13 cDNA that was expressed in the prior study
by Shimozawa et al. (1998) corresponded to a PEX13
cDNA that was missing exon 1 sequences and that en-
coded a truncated protein that lacked the N-terminal 39
amino acids of PEX13. Using our functional comple-
mentation assay, we observed that this truncation re-
duced PEX13 activity to ∼20% of wild type and may
have interfered with the ability of Shimozawa et al.
(1998) to detect rescue. However, the fact that the
PEX13 cDNA used in that study contained an unfa-
vorable context for initiation at the first ATG of the ORF
may also have been a contributing factor; specifically,
the PEX13 cDNA contained a T at the 3 position
relative to the A of the start codon. Studies of efficiently
translated mammalian mRNA indicate that the 3 po-
sition is almost always a purine (usually an A) and that
its replacement with a pyrimidine can result in trans-
lation initiation at downstream start codons rather than
at the first ATG of the ORF (Kozak 1992, 1996). If the
protein product of the truncated PEX13 cDNA used by
Shimozawa et al. (1998) initiated at the next down-
stream ATG, then it would result in the loss of the N-
terminal 145 amino acids of PEX13. We have previously
found that large N-terminal deletions of 100 amino
acids eliminated the function of P. pastoris PEX13,
whereas smaller N-terminal deletions retained significant
PEX13 activity (Gould et al. 1996).
Our results provide strong evidence that the I326T
mutation in PEX13 is the cause of disease in patient
PBD222. The next challenge is to determine how this
mutation affects the role of PEX13 in peroxisome bio-
genesis. A variety of studies have established that the
PTS1 and PTS2 receptors, PEX5 and PEX7, are pre-
dominantly cytoplasmic proteins that serve to shuttle
newly synthesized peroxisomal matrix proteins from the
cytoplasm to the peroxisome (Kunau and Erdmann
1998). However, it is also clear that there are detectable
quantities of the PTS1 and PTS2 receptors associated
with peroxisomes at steady state. PEX13, along with
PEX14 and PEX17, has been implicated in the docking
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of these receptors to the peroxisome membrane, and the
SH3 domain of PEX13 has been implicated in binding
PEX5 (Elgersma et al. 1996; Erdmann and Blobel 1996;
Gould et al. 1996; Huhse et al. 1998; Girzalsky et al.
1999). The PEX13 mutation I326T, identified here in
patient PBD222, lies within the PEX13 SH3 domain and
substitutes a polar residue, threonine, for the hydro-
phobic residue, isoleucine, that is normally found at this
position. As such, the I326T mutation may be expected
to affect the interaction between PEX13 and one ormore
of its interacting proteins. Molecular replacement mod-
eling with the three-dimensional structure of the Fyn
SH3 domain (Musacchio et al. 1994) used as the tem-
plate allowed us to assess the possible structural effects
of the I326T mutation. These modeling experiments sug-
gest that I326 may interact with F293, a residue within
the large RT-loop of the PEX13 SH3 domain, and that
this interaction may stabilize the fold of the SH3 domain.
Replacement of I326 with the polar threonine residue is
predicted to disrupt this interaction with F293, with one
possible result being the destabilization of the RT-
loop—a region of the protein involved in substrate rec-
ognition. Additional experiments to determine the ef-
fects of this mutation on the interaction between PEX13
and its partner proteins should provide important insight
into why the I326T mutation disrupts peroxisomal pro-
tein import.
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